This webinar memorialized pioneering sociologist Jeff McConnell and his impact on HIV prevention science. Updates were presented on pre-exposure prophylaxis (PrEP) research and the implications of Dr. McConnell’s research on sexual networks for how PrEP will be implemented.Find details, slides and full flash webinar here.
Jeff McConnell Memorial Webinar – Audio
HIV Prevention Europe Webinars: Rectal microbicides
The seventh webinar in our series addressing a range of topics in HIV prevention research, hosted jointly by NAM and AVAC, focused on rectal microbicides. Speakers included: Ian McGowan, University of Pittsburgh; Carolina Herrera, Imperial College; Alex Carballo-Dieguez, Columbia University; and Marc-André LeBlanc, IRMA.
The presentation was followed by a Q&A session. Click here for slides and audio from the webinar.
Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PrEP” trials
This 2005 report examines the issues surrounding the tenofovir trials and makes recommendations for ensuring that trials are carried out ethically and that provisions are made for dealing with the results of the trials when they are available. The report also calls for more concerted coordination and advance planning to accelerate evaluation, licensing, and access to PrEP.
Understanding the Results of the AIDSVAX Trial
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Understanding the Results of the AIDSVAX Trial (French)
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Understanding the Results of the AIDSVAX Trial (Spanish)
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Multipurpose Prevention Technologies for Reproductive Health
In May 2011, AVAC, USAID and CAMI convened a group of scientists to discuss and recommend strategies for accelerating the development of multipurpose prevention technologies for protection against unintended pregnancy, HIV and other STIs. This report includes the presentations and discussions from the meeting, as well as recommendations for next steps.
Antiretroviral Treatment for Prevention of HIV and Tuberculosis
Despite considerable evidence supporting the use of antiretroviral therapy (ART) for prevention of HIV and TB illness, death and transmission, only 37 percent of the 35 million people living with HIV were receiving it in 2013. This paper examines ongoing and planned global treatment as prevention studies and addresses research questions related to access and implementation.
Ongoing and Planned PrEP Demonstration and Implementation Studies
This is a summary table of ongoing and planned global PrEP evaluation studies.
Global Investment in HIV Cure Research and Development in 2012
In 2013 the International AIDS Society HIV Cure Resource Tracking group joined with the HIV Vaccines and Microbicides Tracking Working Group to estimate global investments in HIV cure research and produce this short report.